 We also demonstrated that Immunocal was able to reduce glutathione in HepG2 by 20% to 40% and regulated the elevation of glutathione, which was in response to baicalein.In conclusion, Immunocal seemed to enhance the cytotoxicity of baicalein by inducing more apoptosis, this increase in apoptotic cells may be in association with the depletion of GSH in HepG2.This is the first study to demonstrate, in vitro, that Immunocal may function as an adjuvant in cancer treatments.